Advice

in the absence of a submission from the holder of the marketing authorisation:

rituximab (MabThera®) is not recommended for use within NHSScotland.

Indication under review: treatment of patients with moderate to severe pemphigus vulgaris.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice354KB (PDF)

Download

Medicine details

Medicine name:
rituximab (MabThera)
SMC ID:
SMC2193
Indication:
Treatment of patients with moderate to severe pemphigus vulgaris.
Pharmaceutical company
Roche
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
13 May 2019